BioInvent International AB

BioInvent International AB recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. #BioStockSwe #LifeScience

This week, BioInvent's Director Clinical Pharmacology Johan Wallin is in Rome at the Population Approach Group Europe #PAGE2024 annual meeting, presenting the model-informed early clinical development of our lead anti-TNFR2 antibody BI-1808. The poster describes how a model-informed approach can support and optimize clinical development. The aim was to characterize the population pharmacokinetics (PK), receptor occupancy (RO), and concentrations of the target engagement biomarker soluble tumor necrosis factor receptor 2 (sTNFR2) at different BI-1808 doses, to support the dose selection for the dose expansion trial. Data are confirming a wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy. BI-1808 could represent a new class of immunomodulatory agent with the potential to improve efficacy of cancer therapy. As earlier communicated, initial efficacy and safety data from the ongoing Phase 1/2a study show so far: - One complete response (CR), one partial response (PR) that is still improving, and nine patients with stable disease (SD) of 26 evaluable patients in the single agent arm of BI-1808 - Promising signs of efficacy and favorable safety profile in the Phase 1 dose escalation part studying BI-1808 in combination with KEYTRUDA® (pembrolizumab). “The data presented in this poster demonstrate our effective leveraging of a model-informed approach to support dose selection and optimization in the development of our immunomodulatory agent BI-1808," commented Martin Welschof, Chief Executive Officer of BioInvent. “The model confirms the wide potential dose range of BI-1808 and will be beneficial in the selection of doses as our clinical evaluation of the asset continues in the ongoing Phase 1/2a study, which has already produced promising initial safety and efficacy results." #immunooncology #immunotherapy #antibodytherapeutics #biotechnology #lifesciences

Did you miss our KOL event yesterday? No worries, you can watch it here, anytime: https://lnkd.in/dAV8s7yT The KOL event includes a presentation by Alexander Eggermont, MD, PhD (University Medical Center Utrecht), on the topic "Where are we going next with immuno-oncology?" The company management discusses the recently disclosed positive clinical data for our lead, first-in-class antibodies, BI-1808 and BI-1206, recently presented at ASCO and EHA. The data support the promise of FcyRIIB and TNFR2 as important immunotherapy targets. BI-1808 and BI-1206 are BioInvent's two lead programs in a broad pipeline of first- or best-in-class immunomodulatory antibodies for the treatment of cancer: - BI-1808, an anti-TNFR2 antibody, showing promising single-agent efficacy in an ongoing Phase 1/2a trial as a single agent as well as in combination with pembrolizumab for patients with advanced malignancies. - BI-1206, an anti-FcyRIIB antibody, currently being evaluated in two Phase 1/2a trials: in combination with rituximab for patients with non-Hodgkin’s lymphoma (NHL) and in combination with pembrolizumab for patients with solid tumors. Recently disclosed data for BI-1206 show long-lasting responses in heavily pre-treated patients. The event also highlights the upcoming rich news flow for the rest of 2024: - BI-1808 single agent Phase 2a data; YE 2024 - BI-1206 triplet Phase 2a data in NHL; YE 2024 - BI-1910 single agent Phase 1 data H2 2024 - BT-001 pembrolizumab combination Phase 1 data H2 2024   A question and answer session followed the formal presentation, don't miss. #immunooncology #immunotherapy #lifesciences #biotechnology #antibodytherapeutics

Join us today, Tuesday June 18, for a virtual KOL event, at 9 am EDT/3 pm CEST featuring Professor Alexander Eggermont, MD, PhD (University Medical Center Utrecht), who will join company management to discuss the recently disclosed positive clinical data for our lead, first-in-class antibodies, BI-1808 and BI-1206. Register here: https://lnkd.in/dAV8s7yT

The past weekend our CMO Dr Andres McAllister and Dr Johan Wallin, Director Clinical Pharmacology were in Madrid at the European Hematology Association Congress (#EHA2024) presenting the latest clinical Phase 1/2a data for one of our lead assets, BI-1206 in NHL: - First data from the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients. - Further updates from the IV arm; a fifth CR observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients. “We were pleased to share further validating Phase 1/2a data for BI-1206 in NHL during EHA. There is a high unmet need to develop treatments that can overcome resistance and improve the durability of responses to rituximab, an essential part of NHL treatment. We believe BI-1206 has the potential to meet this need,” commented Martin Welschof, Chief Executive Officer of BioInvent. ”To identify the best options and meet the needs of clinicians and patients, we are evaluating BI-1206 administration as both IV and SC. IV dosing so far has produced response rates of a 35% ORR (overall response rate), 29% CRR (cumulative response rate) and 71% DCR (disease control rate), and we see promising early efficacy data from the subcutaneous dosing. In addition, we report an ORR of 56% in the subset of patients with follicular lymphoma (FL). Based on these encouraging results, we plan to initiate a Phase 2a study arm where the BTK inhibitor, acalabrutinib (Calquence®), will be added to the rituximab and BI-1206 combination, which should further increase response rates.” BI-1206 is developed to re-establish the clinical effect of existing cancer treatments such as rituximab and is evaluated as both intravenous (IV) and subcutaneous (SC) administration. #immunotherapy #immunoncology #antibodytherapeutics #lifescience #biotechnology

Looking forward to this event, discussing the exciting BI-1808 and BI-1206 data released at ASCO 2024 and EHA 2024. This marks the start of a hopefully equally news-rich second half of the year! Don't miss.

The BioInvent team - CMO Dr Andres McAllister and Dr Johan Wallin, Director Clinical Pharmacology, together with Dr Kristoffer Staal Rohrberg from Rigshospitalet in Copenhagen, Principal Investigator of the BI-1808 Phase 1/2a clinical study - have had some busy days at ASCO giving color on the latest positive data on our lead assets BI-1808 and BI-1206. The two posters are now public and can be reached here: https://lnkd.in/eTih9uD4 BioInvent’s CEO Martin Welschof commented on the progress for the anti-TNFR2 lead asset BI-1808: “The data evaluating BI-1808 as single agent and in combination with pembrolizumab in patients with solid tumors support our belief that BI-1808 could represent a new class of immunomodulatory agent with the potential to improve the efficacy of cancer therapy. These strong signals of antitumoral activity, especially in these heavily pre-treated patients, are very encouraging". CMO Andres McAllister commented on the anti-FcyRIIB lead asset BI-1206 : “The ability to induce responses in these heavily pre-treated patients, including two durable responses and a stable disease lasting for more than 24 months, is encouraging and supports the importance of blocking FcyRIIB to enhance the activity of immune checkpoint inhibitors.” #immunooncology #immunotherapy #antibodytherapeutics #lifesciences

In the coming weeks, BioInvent is set to present three significant data sets at the American Society for Clinical Oncology’s (ASCO) annual congress and the European Hematology Association’s (EHA) annual meeting. At ASCO, BioInvent will showcase advancements with BI-1808 monotherapy and BI-1206 in combination with Keytruda. At EHA, promising data on BI-2106 will be presented to the expert community. Read the full article from BioStock: https://lnkd.in/dGRf9srN

We are so excited about the clinical data on our two lead candidates, BI-1808 and BI-1206, to be presented at ASCO next Saturday. “The number of targets available for antibody therapy is still limited and there is a high unmet medical need for new treatment options since the vast majority of patients do not respond or stop responding to current treatments. We believe that BI-1206 has the potential to be used in combination with CPIs to overcome immunotherapy drug resistance through its unique anti-FcyRIIB action,” said Martin Welschof, Chief Executive Officer of BioInvent. BioInvent’s Chief Medical Officer Andres McAllister added, “The ability of BI-1206 to induce responses in heavily pre-treated patients, including two durable responses and a stable disease lasting for more than 24 months, is encouraging and supports the importance of blocking FcyRIIB to enhance the activity of immune checkpoint inhibitors.” “We are pleased to present these early data from the Phase 1/2a study evaluating BI-1808 as single agent and in combination with pembrolizumab in patients with solid tumors, which support our belief that the product could represent a new class of immunomodulatory agent with the potential to improve the efficacy of cancer therapy. These strong signals of antitumoral activity, especially in these heavily pre-treated patients, are very encouraging,” said Martin Welschof, Chief Executive Officer of BioInvent. Read the two press releases: https://lnkd.in/eughekWr #immunotherapy #immunooncology #antibodytherapeutics #lifescience #biotechnology

- EXCITING NEWS OUT - Today, we are happy to share exciting new data from our anti-FcyRIIB program BI-1206 for the treatment of NHL. Data from the subcutaneous (SC) arm of the Phase 1/2a study disclosed for the first time, showing 1 complete response, 2 partial responses and 1 stable disease out of 4 evaluable patients. In the IV arm, a fifth complete response is reported, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients. The data will be presented on June 14, 2024, in a poster at the European Hematology Association congress held in Madrid, Spain. “We are pleased to share further validating Phase 1/2a data for BI-1206 in NHL during EHA. There is a high unmet need to develop treatments that can overcome resistance and improve the durability of responses to rituximab, an essential part of NHL treatment. We believe BI-1206 has the potential to meet this need,” commented Martin Welschof, Chief Executive Officer of BioInvent. ”To identify the best options and meet the needs of clinicians and patients, we are evaluating BI-1206 administration as both IV and SC. IV dosing so far has produced response rates of a 35% ORR (overall response rate), 29% CRR (cumulative response rate) and 71% DCR (disease control rate), and we see promising early efficacy data from the subcutaneous dosing. In addition, we report an ORR of 56% in the subset of patients with follicular lymphoma (FL). Based on these encouraging results, we plan to initiate a Phase 2a study arm where the BTK inhibitor, acalabrutinib (Calquence®), will be added to the rituximab and BI-1206 combination, which should further increase response rates.” Read the full press release: https://lnkd.in/dpY-n7um